Arvinas Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Arvinas ha un patrimonio netto totale di $586.0M e un debito totale di $600.0K, che porta il suo rapporto debito/patrimonio netto a 0.1%. Le sue attività totali e le sue passività totali sono rispettivamente $1.2B e $581.1M.

Informazioni chiave

0.1%

Rapporto debito/patrimonio netto

US$600.00k

Debito

Indice di copertura degli interessi	n/a
Contanti	US$1.12b
Patrimonio netto	US$586.00m
Totale passività	US$581.10m
Totale attività	US$1.17b

Aggiornamenti recenti sulla salute finanziaria

Here's Why We're Watching Arvinas' (NASDAQ:ARVN) Cash Burn Situation

Jun 27

Recent updates

Arvinas: Major Catalyst Ahead, But Its History Gives Me Pause

Oct 16

Arvinas, Inc. (NASDAQ:ARVN) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Aug 02

News Flash: Analysts Just Made A Notable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts

Aug 13

There's Reason For Concern Over Arvinas, Inc.'s (NASDAQ:ARVN) Price

May 05

Calculating The Fair Value Of Arvinas, Inc. (NASDAQ:ARVN)

Feb 24

Arvinas initiated Overweight at Barclays on attractive therapeutic platform

Sep 09

Arvinas a buy at Piper Sandler following failure of Sanofi breast cancer treatment

Aug 19

Arvinas: Still Holding, Just Not Buying More

May 23

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( $1.1B ) di ARVN superano le sue passività a breve termine ( $275.9M ).

Passività a lungo termine: Le attività a breve termine di ARVN ( $1.1B ) superano le sue passività a lungo termine ( $305.2M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: ARVN ha più liquidità del suo debito totale.

Riduzione del debito: Il rapporto debito/patrimonio netto di ARVN si è ridotto da 1.5% a 0.1% negli ultimi 5 anni.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: ARVN ha una cash runway sufficiente per più di 3 anni in base al suo attuale free cash flow.

Previsione Cash Runway: ARVN ha una liquidità sufficiente per più di 3 anni se il flusso di cassa libero continua a ridursi ai tassi storici del 20.7 % ogni anno

Arvinas Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Here's Why We're Watching Arvinas' (NASDAQ:ARVN) Cash Burn Situation

Recent updates

Consensus revenue estimates increase by 20%

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Arvinas: Major Catalyst Ahead, But Its History Gives Me Pause

Consensus revenue estimates increase by 23%

Arvinas, Inc. (NASDAQ:ARVN) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Arvinas: Hugely Important Data Catalyst Upcoming - Success May Prove Elusive

Arvinas, Inc.(NasdaqGS:ARVN) dropped from Russell Small Cap Comp Value Index

Here's Why We're Watching Arvinas' (NASDAQ:ARVN) Cash Burn Situation

Arvinas, Inc. Appoints Andrew Saik as Treasurer

Arvinas, Inc. Announces Presentations for Two of Its PROTAC Investigational Programs Targeting BCL6 and LRRK2

Arvinas Announces Promotions of Ian Taylor to President of Research and Development and Angela Cacace to Chief Scientific Officer

Arvinas, Inc. Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress

Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE)

Consensus revenue estimates increase by 17%

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Arvinas, Inc. Appoints Randy Teel as Chief Business Officer

Arvinas, Inc., Annual General Meeting, May 29, 2024

Consensus EPS estimates upgraded to US$5.13 loss

Arvinas, Inc. Appoints Noah Berkowitz as Chief Medical Officer and A Member of the Executive Committee

Arvinas: Behind The Huge Rally

Full year 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates upgraded to US$5.76 loss

Arvinas, Inc. announced that it has received $349.999871 million in funding from a group of investors

What Arvinas, Inc.'s (NASDAQ:ARVN) 28% Share Price Gain Is Not Telling You

Arvinas, Inc. Announces Chief Financial Officer Changes

Arvinas, Inc. Announces Chief Financial Officer Changes

Arvinas, Inc. and Pfizer Inc. Announces That the U.S. Food and Drug Administration Has Granted Fast Track Designation for the Investigation of Vepdegestrant (Arv-471) for Monotherapy

Arvinas, Inc. Announces Appointment of Jared Freedberg as General Counsel

Arvinas, Inc. and Pfizer Inc. Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®?) and Plans to Expand Vepdegestrant Development Program

Price target decreased by 7.5% to US$55.82

New minor risk - Share price stability

Consensus estimates of losses per share improve by 13%

Price target decreased by 7.6% to US$55.80

New minor risk - Shareholder dilution

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 10.0% to US$60.38

Arvinas, Inc. Announces the Presentation of Interim Data from the its Phase 1/2 Clinical Trial for Bavdegalutamide

Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023

Consensus revenue estimates increase by 17%

News Flash: Analysts Just Made A Notable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Arvinas and Pfizer Wins Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway Steering Group for Vepdegestrant

Arvinas and Pfizer Wins Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway Steering Group for Vepdegestrant

New minor risk - Share price stability

Arvinas, Inc. Announces Changes to its Board of Directors

Arvinas, Inc. Announces Interim Data from Phase 1/2 Dose Escalation and Expansion Trial of ARV-766

Consensus revenue estimates increase by 10%, EPS downgraded

First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

There's Reason For Concern Over Arvinas, Inc.'s (NASDAQ:ARVN) Price

Consensus EPS estimates fall by 12%

Calculating The Fair Value Of Arvinas, Inc. (NASDAQ:ARVN)

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Arvinas Announces Changes to Its Board of Directors

Arvinas, Inc. Announces in Post-Hoc Analysis from Phase 2 Cohort Expansion Portion (VERITAC) of Phase 1/2 Study with ARV-471 Expects VERITAC-2 Phase 3 Trial Population Achieve Clinical Benefit Rate of 62.5%

Price target decreased to US$83.90

Arvinas, Inc. Announces Initial Results from Phase 2 Cohort Expansion Portion (VERITAC) of Phase 1/2 Study with ARV-471 Co-Developed with Pfizer Inc

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Arvinas, Inc. Appoints Paul McInulty as Senior Vice President, Regulatory Affairs

Arvinas initiated Overweight at Barclays on attractive therapeutic platform

Arvinas a buy at Piper Sandler following failure of Sanofi breast cancer treatment

Arvinas, Inc. Announces Changes to its Board of Directors

Chief Medical Officer exercised options and sold US$69k worth of stock

Arvinas, Inc. Appoints Lisa Sinclair as Senior Vice President, Corporate Operations

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Arvinas, Inc. Appoints John Northcott as Chief Commercial Officer

Arvinas: Still Holding, Just Not Buying More

Consensus EPS estimates fall by 12%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new directors

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto